This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The interventions considered in the economic analysis were five alternative treatments considered in a recent randomised controlled trial (RCT). The treatment strategies were: the standard approach of sequential single-agent modified de Gramont regimen (MdG) using fluorouracil until treatment failure, followed by single agent irinotecan (strategy A); first-line MdG regimen using fluorouracil until treatment failure, followed by doublet therapy with MdG plus irinotecan (strategy B-ir); first-line MdG regimen until treatment failure, followed by doublet therapy with MdG regimen plus oxaliplatin (strategy B-ox); first-line doublet therapy with MdG regimen plus irinotecan (strategy C-ir); and first-line doublet therapy with MdG regimen plus oxaliplatin (strategy C-ox). Salvage therapy (any chemotherapy initiated after failure of one of the five strategies) options were also offered.
Location/setting
UK/Secondary care.
Methods

Analytical approach:
A decision-tree model was used to extrapolate the results of a single clinical trial (FOCUS trial; Seymour, Maughan, et al. 2007 , see 'Other Publications of Related Interest' below for bibliographic details) over an extended time period. The time horizon of the analysis was 10 years, which covered a time period over which most of the patients in the study population were expected to have died. The authors stated the study perspective to be that of the UK NHS.
Effectiveness data:
The effectiveness data were taken from the FOCUS trial. This was a randomised controlled trial, conducted in the UK, with a sample size of 2,135 patients. Median follow-up of patients was 26.5 months. The main clinical effectiveness estimate of patient survival was derived from the FOCUS trial.
Monetary benefit and utility valuations:
The source of utility values were the responses of patients to the European Quality of life (EQ-5D) questionnaire during the FOCUS trial, which were converted with utility estimates representing the UK population, using a scaled gamma model.
